Elsevier

Biochemical Pharmacology

Volume 78, Issue 7, 1 October 2009, Pages 844-851
Biochemical Pharmacology

Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity α4β2 subunit combination

https://doi.org/10.1016/j.bcp.2009.06.024Get rights and content

Abstract

α4β2 neuronal nicotinic receptors (nAChRs) can exist in high and low sensitivity states possibly due to distinct stoichiometries during subunit assembly: (α4)2(β2)3 pentamer (high sensitivity, HS) and (α4)3(β2)2 pentamer (low sensitivity, LS). To determine if there is a linkage between HS or LS states and receptor-mediated responses in brain, we profiled several clinically studied α4β2* nAChR agonists for the displacement of radioligand binding to α4β2 [3H]-cytisine sites in rat brain membranes, effects on stimulation of [3H]-dopamine release from slices of rat prefrontal cortex and striatum, and activation of HS and LS human α4β2 nAChRs expressed in Xenopus laevis oocytes. Binding affinities (pKi) and potency (pEC50) values for [3H]-dopamine release closely correlated with a rank order: varenicline > (−)-nicotine > AZD3480 > dianicline  ABT-089. Further, a good correlation was observed between [3H]-dopamine release and HS α4β2 pEC50 values, but not between [3H]-dopamine release and LS α4β2. The relative efficacies of the agonists ranged from full to partial agonists. Varenicline behaved as a partial agonist in stimulating [3H]-dopamine release and activating both HS and LS α4β2 nAChRs expressed in oocytes. Conversely, ABT-089, AZD3480 and dianicline exhibited little efficacy at LS α4β2 (<5%), were more effective at HS α4β2 nAChRs, and in stimulating cortical and striatal [3H]-dopamine release ≥30%. In the presence of α-conotoxin MII to block α6β2* nAChRs, the α4β2* α-conotoxin-insensitive [3H]-dopamine release stimulated by these ligands correlates well with their interactions at HS, but not LS. In summary, this study provides support for HS α4β2* nAChR involvement in neurotransmitter release.

Introduction

Neuronal nicotinic acetylcholine receptors (nAChRs) belong to the family of pentameric acetylcholine-gated cation channels and are assembled from twelve subunits, α2–α10 and β2–β4. These subunits combine to form homomeric or heteromeric nAChRs that mediate a wide range of physiological and pharmacological effects in the nervous system. All are thought to be pentameric, comprised of a mixture of alpha-subunits (α2–α6) and beta-subunits (β2–β4) with exceptions of homomers of α7–α9 subunits, or heteromers of α9–α10 subunits [1]. A recent report provided evidence for the existence of a functional α7β2 nAChR in rodent basal forebrain [2]. The α4β2-containing (α4β2*) nAChRs account for 90% of the high affinity nicotine binding sites and are widely distributed throughout the brain including in the cortex, hippocampus, substantia nigra, and ventral tegmental area (reviewed in [3]). The last two regions are particularly important since they are rich in dopaminergic neurons whose function is regulated by various nicotinic subunits including α4β2* subtype and thought to participate in modulating the reinforcing effects of nicotine and other addictive substances (reviewed in [4]) and in CNS disorders such as Parkinson's disease.

Initially, heteromeric α4β2 subunits were thought to exist as a single subunit entity exhibiting high affinity to nicotine [5]. However, a variety of combinations and stoichiometries are possible as evidenced by injecting varying ratios of α4 and α2 cRNA or cDNA [6], [7], [8], [9].

Combination of excess α4 with respect to β2 subunit is thought to generate predominantly (α4)3(β2)2 pentamer with low sensitivity (LS) to ACh (EC50  100 μM), whereas the reverse ratio is thought to favor the (α4)2(β2)3 expression with high sensitivity (HS) to ACh (EC50  1 μM). This concept is supported by studies using linked α4β2 subunits assembled with β2 subunits as (α4β2)2β2 pentamers and with α4 subunits as (α4β2)2α4 pentamers to address the stochiometry of functional receptor assemblies [10]. Other compounds exhibiting differential profiles at HS and LS profiles include a variety of agonists (nicotine, epibatidine, cytisine, 3-Br-cytisine, 3-[2(S)-azetidinylmethoxy]pyridine (A-85380), 5-ethoxy-metanicotine (TC-2559), A-163554 and A-168939) and some antagonists, particularly chlorisondamine [9], [11]. The LS form is thought to be more permeable to Ca2+ than the HS form whereas the HS form is more sensitive to upregulation by chronic nicotine and reduced ambient temperature [12]. Other combinations with various degrees of sensitivities and selectivities for nAChR ligands can be formed with the substitution of other subunits such as α2, α3, α6 or β4 [3]. Like α4β2, HS and LS forms of α3β2 also have been demonstrated, suggesting this may be a general feature of β2-containing nAChR [9]. The α5 and β3 subunits do not participate in the formation of acetylcholine binding sites, but may have accessory or regulatory roles in the receptor affecting the properties of the expressed pentamer. For instance, (α4β2)2 α5 nAChRs were reported to be more permeable to Ca2+ than either (α4β2)2β2 and (α4β2)2α4 pentamers [13]. One brain region that has been demonstrated to be especially rich in the variety of nAChRs present is the striatum with up to six nAChR combinations proposed [14]. Through the use of null mutant mice, immunoprecipitation, and inhibition with α-conotoxin MII, it has been ascertained that there likely exist α4β2, α4α5β2, α6β2, α4α6β2β3, and α6β2β3 combinations as well as the homomeric α7 in the striatum.

However, HS and LS forms of β2-containing nAChR are defined mainly by kinetic (EC50) parameters. Whether both forms are expressed in the CNS and, if so, whether they have different functional roles is not yet fully elucidated. In mouse thalamic synaptosomes, responses to HS α4β2 nAChR selective agonists such as A-163554 and A-168939 suggest that at least the HS form is expressed functionally in that brain region [9]. Whether LS α4β2 nAChR also is expressed and whether the pattern may vary among brain regions remain open questions.

In this study, we hypothesized that there may be differential contributions of HS, (α4)2(β2)3, and LS, (α4)3(β2)2, nAChRs in neurotransmitter release. We addressed the contribution of HS and LS α4β2 to nAChR-mediated [3H]-dopamine release from slices of rat prefrontal cortex and striatum by using a set of five agonists, and compared the pharmacological profiles of transmitter release with those of HS and LS α4β2 nAChRs expressed in Xenopus oocytes and α4β2* ([3H]-cytisine) binding in rat brain. Additionally, since multiple receptor subtypes are involved in nAChR-mediated [3H]-dopamine release in the striatum, α-conotoxin MII was used to distinguish the role of α4β2* from α6β2* nAChRs. Our results suggest that the HS, but not the LS, form of α4β2 nAChR is primarily involved in nicotine-stimulated dopamine release.

Section snippets

Materials

Membranes for radioligand binding studies were prepared from frozen rat brains (PelFreez, Rogers, AR, USA). For neurotransmitter release studies, male Sprague–Dawley rats were used from Charles River Laboratories (Portage, MI, USA, 250–400 g). Oocytes were obtained from adult female Xenopus laevis frogs (Blades Biological Ltd., Cowden, Edenbridge, Kent, UK). Animals were cared for in accordance with the Institutional Animal Care Committee guidelines that meet the guidelines of the National

Results

Binding affinities of nAChR ligands at α4β2* nAChRs were assessed by displacement of [3H]-cytisine binding to rat brain membranes (Table 1). Varenicline had a Ki value of 0.08 nM, which was 10-fold higher than (−)-nicotine (Ki = 0.94 nM). The other three compounds also had relatively high affinity with Ki values of 2.7 nM for AZD3480, 11.4 nM for dianicline, and 14.1 nM for ABT-089.

Changes in the stoichiometry of the nAChR pentameric structure can be influenced by the ratio of human subunit cRNAs

Discussion

Previous studies have demonstrated that α4β2 nAChRs can exist in high sensitivity (HS) and low sensitivity (LS) states dependent on stoichiometry [6], [7], [8], [9]. However, the contributions of high and low sensitivity combinations to functional effects mediated by nAChR ligands, as for example dopamine release, remain unclear. Release of [3H]-dopamine from rat brain slices evoked by nicotine and nAChR agonists is mediated by multiple receptor subtypes, including α4β2-containing and

Acknowledgement

This work was supported by Abbott Laboratories.

References (32)

  • A.C. Collins et al.

    The road to discovery of neuronal nicotinic cholinergic receptor subtypes

    Handb Exp Pharmacol

    (2009)
  • P.J. Whiting et al.

    Purification and characterization of a nicotinic acetylcholine receptor from chick brain

    Biochemistry

    (1986)
  • R. Zwart et al.

    Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes

    Mol Pharmacol

    (1998)
  • B. Buisson et al.

    Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function

    J Neurosci

    (2001)
  • M.E. Nelson et al.

    Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors

    Mol Pharmacol

    (2003)
  • C.A. Briggs et al.

    Untranslated region-dependent exclusive expression of high-sensitivity subforms of α4β2 and α3β2 nicotinic acetylcholine receptors

    Mol Pharmacol

    (2006)
  • Cited by (38)

    • Analysis of neuronal nicotinic acetylcholine receptor α4β2 activation at the single-channel level

      2016, Biochimica et Biophysica Acta - Biomembranes
      Citation Excerpt :

      Due to differences in agonist sensitivity and receptor subtype localization in some cases, it is supposed that both subtypes would perform different functions [9]. HS subtype mediates glutamate release in prefrontal cortex and striatum [17,24–26] but also LS subtype has been implicated in this function in the prefrontal cortex [26]. Using the LS site-selective agonist NS9283 [27], it was demonstrated that this subtype participates in cognitive function and analgesia, opening the possibility to use this kind of drugs as cognitive enhancers in patients with Alzheimer disease or neuropathic pain [28,29].

    • Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at cys-loop receptors

      2013, Journal of Biological Chemistry
      Citation Excerpt :

      Interestingly, such receptor stoichiometry differences can greatly affect PAM actions as illustrated by findings that two α4β2 PAMs, Zn2+ and NS9283, are both completely specific for 3α:2β receptors (9, 25). No PAMs have yet been shown to modulate the 2α:3β stoichiometry α4β2 receptors, an unfortunate fact given their potential importance in mediating dopamine release in the striatum (26). In the present study, we describe a novel α4β2 nAChR PAM, NS206, which modulates ACh-evoked responses at both common α4β2 receptor stoichiometries (i.e. 2α:3β and 3α:2β receptors).

    • Involvement of α4β2 nicotinic acetylcholine receptors in working memory impairment induced by repeated electroconvulsive seizures in rats

      2013, Epilepsy Research
      Citation Excerpt :

      In immunohistochemical study using a single section per rat, repeated administration of ECS caused a reduction in α4 nAChR expression in the prefrontal prelimbic cortex and the hippocampal areas CA1 and CA3. Previous studies reported that the α4β2 partial agonist varenicline increased working memory-related brain activity in abstinent smokers (Loughead et al., 2010) and stimulated dopamine release from the PFC in rats (Anderson et al., 2009). In addition, Davis et al. (2007) reported a critical role for α4β2 nAChRs in the hippocampus in mediating the enhancing effect of nicotine on contextual fear conditioning (Davis et al., 2007).

    View all citing articles on Scopus
    1

    Present address: Dept. Neuroscience, Rosalind Franklin University, 3333 Green Bay Road, North Chicago, IL 60064, USA.

    View full text